Coated aldehyde oxystarch for reducing toxins in kidney failure
Part of Kidney & urinary clinical trials.
This trial tests a new oral medication, coated aldehyde oxystarch, for people on dialysis. It aims to lower certain waste products in the blood that are hard to remove with standard dialysis, which may help reduce long-term complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been on maintenance dialysis (hemodialysis or peritoneal dialysis) for at least 3 months.
- You have not changed your dialysis schedule or medications that affect gut bacteria in the last month.
- You do not have a history of serious gut problems (like inflammatory bowel disease, prior stomach surgery, or bowel obstruction).
- You have not had a heart attack, stroke, or been hospitalized for heart problems in the last 3 months.
- You are not allergic to the study medication (coated aldehyde oxystarch).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
This Phase 3 trial studies how well a new peritoneal dialysis solution works and whether it is safe. It’s meant for adults with kidney failure who already do a specific type of at-home dialysis.
This trial tests whether adding a special blood-filtering device (hemoadsorption) to your regular dialysis treatment can reduce uncomfortable symptoms caused by kidney failure, like fatigue or itching. Researchers will track how you feel over time compared to standard dialysis alone.
Hear when a new End Stage Renal Disease on Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.